I-Mab Signs Agreement to Divest its Assets and Business Operations in China

February 7, 2024

https://www.prnewswire.com/news-releases/i-mab-signs-agreement-to-divest-its-assets-and-business-operations-in-china-302055853.html

ROCKVILLE, Md., Feb. 7, 2024 /PRNewswire/ —  I-Mab (the “Company“) (NASDAQ: IMAB), a global biotech company exclusively focused on bringing highly differentiated immunotherapies and biologics for cancer treatment to patients around the world, today announced that as part of its strategy to become a U.S.-based biotech, its Chinese subsidiaries have entered into definitive agreements with I-Mab Biopharma (Hangzhou) Co., Ltd. (the “Hangzhou Company“), an unconsolidated affiliate of the Company, and a group of China-based investors to divest the Company’s assets and business operations in China.

Read more at prnewswire.com

Related news for (IMAB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.